1 / 23

Management of pain in diabetic neuropathy

Management of pain in diabetic neuropathy. Definition of diabetic neuropathy : heterogeneous group of diseases that affect the autonomic and peripheral nervous systems of patients suffering from diabetes.Incidence : - unknow, estimated 220 million people in 2010 - 28 to 50 % of patie

madrona
Télécharger la présentation

Management of pain in diabetic neuropathy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. Management of pain in diabetic neuropathy F. Benot

    2. Management of pain in diabetic neuropathy Definition of diabetic neuropathy : heterogeneous group of diseases that affect the autonomic and peripheral nervous systems of patients suffering from diabetes. Incidence : - unknow, estimated 220 million people in 2010 - 28 to 50 % of patients suffer from diabetes - > 50% of individuals aged > 60years

    3. Management of pain in diabetic neuropathy Pathophysiology : - multifactorial - role of persistant hyperglycemia (polyols pathway) - ? nerve sorbitol ? ? nerve flow ? capillary pathology ? - ? decrease nerve myoinisitol ? ? nerve Na/K ? ? ? nerve velocity ? signs and symptoms neuropathy - Autoimmune mechanisms ( antineuralantibodies, antiphospholipid antibodies) - microvascular mechanisms - other mechanisms ( genetic, environmental factors, structural changes,)

    4. Management of pain in diabetic neuropathy Evaluation of pain in diabetic neuropathy : Diagnosis of diabetic neuropathy Evaluate the intensity of pain (scale) Distinguisch - the location of attempt (symetric or focal and multifocal) on basis of sensitive or motor topography - adverse consequences : depression, decreased socialisation, sleep disturbance, impaired ambulation and increased health care resource use and costs. JAGS MAY 1998 vol.46 NO.5

    5. Management of pain in diabetic neuropathy Presentation : - focal - peripheral or thoracic location - pain: sudden, acute, severe - resolve inexplicably - truncal - coincide .extreme glycemia (hypo/hyper) .weight (gain/lost) - pain: severe dysesthesic, worse at night - spontaneously resolve ( 6/12 months)

    6. Management of pain in diabetic neuropathy Presentation : - mixed symmetrical distal - sensory, autonomic and motor nerves - symmetrical involvement of extremities - sensory loss, dysesthesia, painfull paresthesia - worse at night - deep tendon reflexes disappear - motor involvment, weakness, atrophy

    7. Management of pain in diabetic neuropathy Treatment : - preventive measures : - control of blood sugar ( UKPDS, DCCT ) - prevention of trauma (careful,skin,) - orthotics devices (orthoses) - promptly treat skin ulcers or infections

    8. Management of pain in diabetic neuropathy Treatment : - Nonpharmacological : - streching exercices - electrotherapy (tens) - psychological aspect - acupunture - pharmacological : 2 pathways ? target the different steps of physiopathologics disorders by hyperglycemia ? target pain symptoms

    9. Management of pain in diabetic neuropathy Treatment : ? neurodestructive effect by

    10. Treatment : ? treat diabetic neuropathy - aldose reductase inhibitors : - decrease the accumulation of sorbitol - sorbinil ( adenopathies, cytopenia) - tolrestat, zenarestat : some improvements in symptoms (renal toxicity, hepatic dysfunction) - fidarestat : well tolerate, Eparlestat use in japan only. - no evidence to support their use - linoleic acid : - ? symptoms, best electromyography - no evidence to support their use Diabetes Care vol.24 NO 10, oct.2001 Management of pain in diabetic neuropathy

    11. Management of pain in diabetic neuropathy Treatment : ? treat diabetic neuropathy

    12. Treatment : ? treat diabetic neuropathy - neurotropins : - nerve growth factors, insulin like growth factor - no evidence to support their use - immunoglobulins : - proximal or/and motor nerves inflammatory location - cost - no evidence to support their use Management of pain in diabetic neuropathy

    13. Management of pain in diabetic neuropathy Treatment : ? target pain symptoms - antidepressants - tricyclic : - most effective, blockade postsynaptic norepinephrine and serotonin reuptatake - cholinergic side effects (hypotension, retention,) - 10 mg at bed time ( ami or nor-triptyline) titrate up to 25 mg as side effects permit. - alone or in addition with gabapentin. - desipramine (pertofran), nortriptyline : fewer adverse effects and sedative effects pharmacotherapy 2001; 21 (9): 1070-1081

    14. Management of pain in diabetic neuropathy Treatment : ? target pain symptoms - antidepressants : - serotonin reuptake inhibitors : - less side effects - less effective than tricyclics - maprotiline ( ludiomil) : - less effective than tricyclics and similar adverse side effects. - trazodone : - effective but limited by the absence of placebo control studies. - venlafaxine : -minimal histaminic, muscarinic and adrenergic side effects - no placebo control study

    15. Management of pain in diabetic neuropathy Treatment : ? target pain symptoms - anticonvulsants : - gabapentin : - action unknow - well tolerated ( somnolence, ataxia,) - resuts similar in comparison with amitriptyline - no mean dosage ( between 900 mg/d to 3600 mg/d) - eliminated by renal route - carbamazepine : - blocks presynaptic action, decrease the release excitatory neurotansmitters and blocking postsynaptic repetitive discharge. - rapid onset of analgesic action - 50-100 2X/d max. 1200mg/d - adverse effects ( aplasic anemia, agranulocytosis,...) pharmacotherapy 2001; 21 (9): 1070-1081

    16. Management of pain in diabetic neuropathy Treatment : ? target pain symptoms - anticonvulsants : - phenytoin : - improvement in pain and paresthesia (100 mg 3 or 4/d) - titration of 5 to 20 mg/L same than placebo ?conflicting evidence - numerous adverse effects ( blood dyscrasias, hepatotoxicity,...) - benzodiazepines : - more studies needed - lamotrigine (Lamictal) : - induced dose dependent analgesia in rat - no more efficacy than placebo. The cochrane library 2002 issue 2

    17. Management of pain in diabetic neuropathy Treatment : ? target pain symptoms - anticonvulsants : - valproic acid :- used in neuropatic pain due to peripheral disorders. more randomised trials are necessary for diabetes antiarrythmics : - mexiletine : - block sodium channels, unable to give pain signals - useful when pain manifests as sharp lancinating or burning pain. (150 to 200 mg2x/d) - poorly tolerated - lidocaine : - sodium channel-blocking effect, - intraenously 5mg/kg (30 to 45 min.) - more studies needed

    18. Management of pain in diabetic neuropathy Treatment : ? target pain symptoms - analgesics : - tramadol : - pain relief unknown and not correlated with serum concentration - potential abuse and development of pain tolerance - NSAIDs : - some pain relief - gastrointestinal and renal side effects - opoids : - adjuvant therapy relief pain more quickly - analgesic tolerance - high doses needed to relieve pain - side effects

    19. Management of pain in diabetic neuropathy Treatment : ? target pain symptoms - antiparkinsonism agents : - levodopa :- effective (100 mg/d), no patient with side effect in a little study (25 patients) - alpha-agonists : - clonidine : - 20 % response vs placebo for sharp and shooting pain.(0.1 mg 2x/d to 0.3mg 2x/d) - transdermal administration (1x7d) - side effects limit the use

    20. Management of pain in diabetic neuropathy Treatment : ? target pain symptoms - others : - pentoxifylline : study limited by lack of placebo control improve de viscosity and the blood flow ? symptoms scores, side effects (arrythmias,) ? Conflicting results - dextromethorphan : - low affinity antagonist properties to the glutamate receptor (when activated it induces a sensation of dull and pain) - average dosage 381 mg/d ? more studies with different dosis needed

    21. Management of pain in diabetic neuropathy -Treatment : ? target pain symptoms - others : - protein kinase C : - isoforms prevent the development of diabetic nerve dysfunction - attractive drug discovery but more studies needed to demonstrated precise mechanism expert opin.investig.Drugs 2001 10 : 1653-1664 capsaicin : topical agent : - depletion of substance P. - few systemic adverse effects - pain reduction (40 % vs 27.8% placebo) - good option if oral agents not tolerated - optimal efficacity with 3 or 4 /d

    22. Management of pain in diabetic neuropathy Take home messages : - good blood glucose control - Tricyclics are the most studied and considered as first-line therapy - desipramine is considered as first choise for elderly - anticonvulsants are second-line agents : gabapentin

    23. Management of pain in diabetic neuropathy Take home messages : Capsaicin good alternative or adjuvant Other drugs have shown some efficacy in trials with small number of patients The adverse effect profile of a drug should be weighed against possible benefits

    24. Management of pain in diabetic neuropathy References: 1 .Ivo W. Tremont-lukats, Carla Megeff and Misha-Miroslav Backonja: Anticonvulsants for neuropathic pain syndromes. Drugs 2000 Nov. 60(5): 1029 - 1052. 2. Diabetes Control and Complication Trial Research Group. (DCCT): The effect of intensive treatment of diabetes on the development and progrssion of long-term complications in insulin-dependent diabetes mellitus. N.Engl.J.Med. 1993;329:977-86. 3. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulfonylureascor insulin compared with conventional treatment and risk of complications in patients with 2 diabetes (UKPDS 33) Lancet 1998; 352:837-853. 4. Management of hyperalgesic diabetic neuropathy. Journ. Annu. Diabetol. Hotel Dieu. 2000; 139-44 review. 5. Patrick G. Jensen and Jennifer R. Larson: Management of painful diabetic neuropathy drugs and aging 2001; 18(10) 737-749.

More Related